Review





Similar Products

86
Kowa Company acuity bcva
Acuity Bcva, supplied by Kowa Company, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pmc13160835-88-17-24?v=Kowa+Company
Average 86 stars, based on 1 article reviews
acuity bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc bcva
Bcva, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pm41927600-103-13-21?v=Cell+Signaling+Technology+Inc
Average 86 stars, based on 1 article reviews
bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Precision Vision acuity bcva
Acuity Bcva, supplied by Precision Vision, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pm41912321-23-6-16?v=Precision+Vision
Average 86 stars, based on 1 article reviews
acuity bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Luminopia Inc bcva
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Bcva, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pmc13123015-139-7-0?v=Luminopia+Inc
Average 86 stars, based on 1 article reviews
bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Luminopia Inc bcva gains
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Bcva Gains, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pmc13123015-108-0-4?v=Luminopia+Inc
Average 86 stars, based on 1 article reviews
bcva gains - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Luminopia Inc luminopia improved bcva
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Luminopia Improved Bcva, supplied by Luminopia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pmc13123015-161-1-1?v=Luminopia+Inc
Average 86 stars, based on 1 article reviews
luminopia improved bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Precision Vision bcva
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Bcva, supplied by Precision Vision, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pm41839400-48-0-11?v=Precision+Vision
Average 86 stars, based on 1 article reviews
bcva - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc bcva change
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Bcva Change, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/pm41712521-168-5-15?v=Cell+Signaling+Technology+Inc
Average 86 stars, based on 1 article reviews
bcva change - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Wolters Kluwer Health non recurrent rd group id m f age eye bcva n
Outline of study of registry patients who have completed treatment <t>with</t> <t>Luminopia.</t> (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean <t>BCVA</t> (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals
Non Recurrent Rd Group Id M F Age Eye Bcva N, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcva/10__1097_slash_iae__0000000000004777-281-6-2?v=Wolters+Kluwer+Health
Average 86 stars, based on 1 article reviews
non recurrent rd group id m f age eye bcva n - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Article Snippet: Luminopia showed greater improvement in lines of BCVA compared to glasses alone after 12-weeks of treatment (1 h 6 days per week) [ , ].

Techniques:

BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Article Snippet: Luminopia showed greater improvement in lines of BCVA compared to glasses alone after 12-weeks of treatment (1 h 6 days per week) [ , ].

Techniques:

Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Article Snippet: BCVA gains achieved with Luminopia were maintained regardless of whether physicians recommended additional follow-up amblyopia treatment.

Techniques:

BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Article Snippet: BCVA gains achieved with Luminopia were maintained regardless of whether physicians recommended additional follow-up amblyopia treatment.

Techniques:

Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: Outline of study of registry patients who have completed treatment with Luminopia. (A) Flow diagram of patient enrollment and disposition. Of 126 patients who completed Luminopia treatment, 60 had follow-up data > 6 weeks post-treatment and were included in the durability analysis. Lost to follow-up rate: 5.5% (7/126) (B) Mean BCVA (logMAR) in the amblyopic eye at baseline, treatment end, and final follow-up for the 60-patient durability cohort. Error bars represent 95% confidence intervals

Article Snippet: While Luminopia improved BCVA in all subgroups, subgroup analysis identified which children received the greatest benefit.

Techniques:

BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Journal: BMC Ophthalmology

Article Title: Real world gains stable in children with amblyopia following digital dichoptic treatment: PUPiL registry results

doi: 10.1186/s12886-026-04747-3

Figure Lengend Snippet: BCVA outcomes comparing patients prescribed alternative treatments to those with no additional treatment. Mean BCVA (logMAR) at baseline, treatment end, and final follow-up for patients with no additional amblyopia treatment recommended after Luminopia ( n = 39) versus those recommended additional treatment ( n = 21). “Additional treatment” refers to penalization therapy (patching or atropine); all patients continued optical correction. Error bars represent 95% confidence intervals

Article Snippet: While Luminopia improved BCVA in all subgroups, subgroup analysis identified which children received the greatest benefit.

Techniques: